Bespak helps Zogenix to develop Intraject product
Zogenix, a specialty pharmaceutical company has signed a deal with manufacture of specialty medical devices, Bespak, over the commercialisation its sumatriptan Intraject delivery system.
Zogenix, a specialty pharmaceutical company has signed a deal with manufacture of specialty medical devices, Bespak, over the commercialisation its sumatriptan Intraject delivery system.
Sumatriptan Intraject is a needle-free, single-use, disposable, subcutaneous delivery technology designed to provide the fastest possible relief of migraine.
Its developer, Zogenix, is a private company with offices in Emeryville and San Diego, California. The company is looking to compete in the $2.5 bn triptan segment of the migraine market. Stephen Farr, president and coo of Zogenix, said: We are currently building towards commercial manufacturing with an anticipated 505(b)2 NDA submission in 2007..
Bespak has facilities in King's Lynn and Milton Keynes in the UK, Indianapolis, Indiana and Kent, Ohio in the US, and Mumbai, India. Its commercial manager, Scott Kellogg said the company would be finalising a supply agreement for the actuator assembly and other components of the Intraject device in the near future.